Biogen inks $411M neurodegeneration pact with protein degrader biotech TrimTech
Biogen has partnered with TrimTech in a $411 million deal to develop protein degraders for neurodegenerative diseases like Alzheimer's and Parkinson's. TrimTech will use its TRIM21-based TRIMTAC and TRIMGLUE platforms to clear disease-causing protein aggregates, marking a major validation for the young biotech.

Original image temporarily unavailable
Collaboration Details
Biogen has entered into a biobucks agreement with U.K.-based TrimTech worth up to $411 million, which includes $32 million in upfront and research milestone payments. Under the pact, Biogen secures an exclusive global license to small molecule protein degraders developed through TrimTech's proprietary platform.
Technology and Targets
TrimTech focuses on using the E3-ligase TRIM21 to clear disease-causing protein aggregates. Its approach features bispecific chimeric molecules called TRIMTAC and mutual binding facilitator TRIMGLUE, offering an alternative to standard PROTACs. The company targets neurodegenerative conditions such as Huntington’s, Alzheimer’s, and Parkinson’s.
Industry Context
Founded in 2023, TrimTech previously raised a $47 million seed round involving major players like Johnson & Johnson, Eli Lilly, and Pfizer. This new agreement reinforces the growing interest from major drugmakers in targeted protein degradation for challenging diseases.
View selection rationale
Importance 77/100
About this brief
- Content type
- News summary
- Source type
- Publisher report
- Original source
- Fierce Biotech ↗
- Source published
- Process
- AI-assisted discovery, translation, summarisation, classification and scoring; standards and corrections are maintained by the editorial desk.
- Verification
- The original URL and publication metadata are retained. This brief is not independently fact-checked unless explicitly stated.
- Published by
- Polyemergence Editorial Desk · PolyEmergence Pte Ltd.
- Conflict disclosure
- No financial or commercial conflict declared.